Navigation Links
Campbell Alliance Clinical Development Practice to Conduct Two Workshops at 44th DIA Annual Meeting
Date:6/17/2008

ice President in the Clinical Development practice. He specializes in helping clients improve their clinical development operations and business processes to optimize the flow of critical information, increase the efficacy of key processes, and enhance organizational capabilities. Mr. Dietlin earned his MBA from DePaul University's Kellstadt Graduate School of Business and has a BA from Loyola University of Chicago.

On the day after Mr. Dietlin's workshop, Tuesday, June 24, Mr. Tyson will conduct a workshop titled "Becoming a Sponsor of Choice for Clinical Investigators" from 8:00 am to 9:30 am. The workshop, which is part of the Clinical Trial Management/Clinical Supplies track, will discuss key factors driving investigators' choices of clinical study sponsors. It will also explore tactics for identifying a pharmaceutical or biotech company's strengths and weaknesses with respect to conducting clinical trials, as well as examine strategies for improving a company's relationship with the study sites and investigators it values most.

"It's critical that a pharmaceutical company do everything it can to be the study sponsor that sites prefer to work with -- the sponsor of choice -- because there are so many clinical trials that are competing for the same patients," Mr. Tyson said. "Companies will gain a clear advantage if they understand what's behind an investigator's or study site's decision to work with a particular sponsor," he said.

As the head of Campbell Alliance's Clinical Development Practice, Mr. Tyson leads a team that provides a range of operational improvement services to clinical development organizations within pharmaceutical and biotech companies, as well as at leading contract research organizations (CROs). He is a veteran of numerous electronic-data-capture-related initiatives, and brings a wealth of knowledge and experience in process improvement, organizational design, and clinical development to his consulting engagements.


'/>"/>
SOURCE Campbell Alliance
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
2. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
3. Campbell Alliance Named Best Place to Work by Triangle Business Journal
4. Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver
5. Campbell Alliance Launches New Practice Area Focused on Trade and Distribution
6. Campbell Alliance Trade and Distribution Practice to Chair CBI 3rd Annual Fee for Service and EDI Data Management Conference
7. Campbell Alliance Brand Management Practice to Discuss Managing Launch Logistics at the EyeForPharma Oncology Summit
8. Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBIs Early Commercialization Conference
9. Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference
10. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
11. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , ... July 29, 2015 , ... The third Medical ... combination products , in particular, drug/device combinations. The current system received a score ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available ... NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells for extreme ... are able to enter fat cells, inhibiting the formation of new fat. Upon ...
(Date:7/28/2015)... A n ew UK company ... commercialising innovative medicines to transform patient quality of life and ... team; blue chip investor ... Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces that it ... blue chip institutional investors and simultaneously acquired a portfolio of ...
(Date:7/28/2015)... July 28, 2015 Seahorse Bioscience, the ... is the provider of XF Technology which is ... research areas. As the links between mitochondrial function ... metabolism is escalating rapidly.   Recently, ... Nature Publishing Group (NPG) featuring XF Technology, including ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3
... Inc. (NYSE: BMR ) today announced it will ... after the market closes on Wednesday, November 3, 2010. ... Kent Griffin, President, and Greg N. Lubushkin, Chief Financial Officer, ... Time on Thursday, November 4, 2010 to discuss the company,s ...
... announced a partnership to advance the use of biofuels by ... effort involves entrepreneurs John Fox ,92 and Wayne Arden, who ... achieve multiple benefits, including reducing risks to American troops and ... With energy demands growing at home bases along with ...
... Generex Biotechnology Corporation (Nasdaq: GNBT, www.generex.com ) announced ... to the Company and a member of the Company,s ... of the reverse stock split proposal being considered at ... "Having been intimately involved in the drug development world ...
Cached Biology Technology:BioMed Realty Trust to Report 2010 Third Quarter Results 2Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defense's Net Zero Energy Initiative 2Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defense's Net Zero Energy Initiative 3Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defense's Net Zero Energy Initiative 4Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 2Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 3Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 4
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... HOUSTON (Aug. 20, 2008) The genetic code of a ... of genes function in humans and other species. A study ... the genetic code of Trichoplax , a simple saltwater creature ... common household aquarium. "We,re trying to identify, in the ...
... biodegradable polymers called polyketals and their derivatives may improve ... acute liver failure and inflammatory bowel disease by delivering ... locations in the body. "The polyketal microparticles we ... inside the body to the diseased area as quickly ...
... Researchers here have found a way to convert ethanol ... new catalyst makes hydrogen from ethanol with 90 percent ... Umit Ozkan, professor of chemical and biomolecular engineering ... is much less expensive than others being developed around ...
Cached Biology News:Genome of saltwater creature could aid understanding of gene grouping 2Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 2Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 3A better way to make hydrogen from biofuels 2A better way to make hydrogen from biofuels 3
Whole blood is collected from healthy pigs (mixed breed, either sex) at the time of slaughter, refrigerated within 6 hours, processed within 24 hours and frozen at -20ºC....
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
... Kit, Protein, 1. Based on the ... the kit gives essentially colorless backgrounds ... Kit, Protein provides convenient, reproducible and ... gels in less than two hours.The ...
Biology Products: